Hong Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hong Yu has a total of 113 co-authors. Here are the top co-authors by number of shared publications:
Fen Du
Taikang Medical School (School of Basic Medical Sciences), Wuhan University, Wuhan, China
7 shared publicationsJia Cao
Department of Biochemistry and Molecular Biology, Hubei Provincial Key Laboratory of Developmentally Originated Disease Wuhan University School of Basic Medical Sciences Wuhan Hubei China
7 shared publications- Bai-Fang Zhang
Department of Biochemistry and Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan University TaiKang Medical School (School of Basic Medical Sciences), Wuhan, China
3 shared publications Daping Fan
Department of Cell Biology and Anatomy, School of Medicine, University of South Carolina Columbia, SC, USA
3 shared publications- Dongfang Wu
Department of Pharmacy, Zhongnan Hospital of Wuhan University, Wuhan, China
3 shared publications Feifei Li
Department of Biochemistry and Molecular Biology, Hubei Provincial Key Laboratory of Developmentally Originated Disease, Wuhan University School of Basic Medical Sciences, Wuhan, Hubei 430071, China
3 shared publications
Latest Publications
- Open Access
- 7 October 2025
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 57 (10) , 2331-2343
Fas apoptotic inhibitor molecule 2 mitigates metabolic dysfunction-associated fatty liver disease through autophagic CRTC2 degradation
Lysosomal membrane proteins play fundamental roles in the lysosomal degradation of proteins and are attractive drug targets for metabolic dysfunction-associated fatty liver disease (MAFLD). Fas apoptotic inhibitory molecule 2 (FAIM2), a lysosomal membrane protein, has been recognized as an inhibitor of apoptosis in a variety of diseases. Here we reveal that FAIM2 is an inhibitor of fatty acid synthesis and suppresses MAFLD. FAIM2 protein expression is decreased in MAFLD. Moreover, FAIM2 is degraded by the E3 ubiquitin ligase NEDD4L through the catalysis of K48-linked ubiquitination. High-fat and high-cholesterol diet-induced hepatic steatosis, inflammation and fibrosis are aggravated in Faim2-knockout mice and alleviated in mice with AAV8-mediated FAIM2 overexpression. Furthermore, in hepatocytes, FAIM2 knockout increases the expression of genes related to fatty acid synthesis, while overexpressing FAIM2 exhibits the opposite effect. Mechanistically, FAIM2 directly interacts with CREB-regulated transcription coactivator 2 (CRTC2), a prominent regulator of lipid metabolism, and mediates its degradation through autophagy. Specifically, we find that the N terminus of FAIM2, which interacts with CRTC2 and LC3, is required for autophagic degradation of CRTC2. Collectively, our findings reveal that FAIM2 acts as a fatty acid synthesis inhibitor in MAFLD by promoting the autophagic degradation of CRTC2 and that FAIM2–CRTC2 may be a promising therapeutic target.
- 7 October 2025
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 57 (10) , 2331-2343
Open AccessFas apoptotic inhibitor molecule 2 mitigates metabolic dysfunction-associated fatty liver disease through autophagic CRTC2 degradation
Lysosomal membrane proteins play fundamental roles in the lysosomal degradation of proteins and are attractive drug targets for metabolic dysfunction-associated fatty liver disease (MAFLD). Fas apoptotic inhibitory molecule 2 (FAIM2), a lysosomal membrane protein, has been recognized as an inhibitor of apoptosis in a variety of diseases. Here we reveal that FAIM2 is an inhibitor of fatty acid synthesis and suppresses MAFLD. FAIM2 protein expression is decreased in MAFLD. Moreover, FAIM2 is degraded by the E3 ubiquitin ligase NEDD4L through the catalysis of K48-linked ubiquitination. High-fat and high-cholesterol diet-induced hepatic steatosis, inflammation and fibrosis are aggravated in Faim2-knockout mice and alleviated in mice with AAV8-mediated FAIM2 overexpression. Furthermore, in hepatocytes, FAIM2 knockout increases the expression of genes related to fatty acid synthesis, while overexpressing FAIM2 exhibits the opposite effect. Mechanistically, FAIM2 directly interacts with CREB-regulated transcription coactivator 2 (CRTC2), a prominent regulator of lipid metabolism, and mediates its degradation through autophagy. Specifically, we find that the N terminus of FAIM2, which interacts with CRTC2 and LC3, is required for autophagic degradation of CRTC2. Collectively, our findings reveal that FAIM2 acts as a fatty acid synthesis inhibitor in MAFLD by promoting the autophagic degradation of CRTC2 and that FAIM2–CRTC2 may be a promising therapeutic target.
- 27 September 2025
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 241, 498-510
Methionine sulfoxide reductase A deficiency impairs zebrafish heart regeneration via inhibiting prohibitin 2-Pink1-mediated mitophagy
- 27 September 2025
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 241, 498-510
Methionine sulfoxide reductase A deficiency impairs zebrafish heart regeneration via inhibiting prohibitin 2-Pink1-mediated mitophagy
- 1 September 2025
- Published by Wiley in The FASEB Journal
- Vol. 39 (17) , e70999
ApoE Mimetic Peptide‐MsrA Fusion Protein Restores HDL Function and Ameliorates Atherosclerosis via Circulatory Redox Remodeling in SR‐BI Deficient Mice
The redox imbalance in circulation can lead to inflammation and cellular damage in vascular walls, which plays a crucial role in atherogenesis. We previously designed an apolipoprotein E (ApoE) mimetic peptide, EpK, which can reduce atherosclerosis in ApoE‐deficient mice by binding high‐density lipoprotein (HDL). Meanwhile, hepatic overexpression of methionine sulfoxide reductase A (MsrA) can exert indirect anti‐atherosclerotic effects. Therefore, exploring biomolecules that directly promote circulatory redox rebalance is significant for the therapy of atherosclerotic cardiovascular diseases (ASCVD). MsrA was recombined with EpK to achieve the secretory expression of EpK‐MsrA. Our experiments revealed that EpK and EpK‐MsrA significantly improved the oxidative state and inflammatory composition of dysfunctional HDL and promoted hepatic cholesterol uptake and excretion, thereby alleviating atherosclerosis and hepatic steatosis in scavenger receptor class B type I deficient (SR‐BI −/− ) mice. Furthermore, compared with EpK, EpK‐MsrA had a stronger anti‐inflammatory and regulatory effect on HDL functional proteins, such as apolipoprotein AI (ApoAI), paraoxonase 1 (PON1), and lecithin cholesterol acyltransferase (LCAT), thereby further reducing atherosclerosis. Additionally, exogenous EpK‐MsrA may be able to regenerate its antioxidant activity through EpK recycling. This study suggests that novel secreted EpK‐MsrA can combine the different antioxidant mechanisms of EpK and MsrA, significantly improve the functional proteins related to lipid metabolism and inflammation, and effectively alleviate atherosclerosis in SR‐BI −/− mice, which may be a promising strategy for the treatment of ASCVD.
- 1 September 2025
- Published by Wiley in The FASEB Journal
- Vol. 39 (17) , e70999
ApoE Mimetic Peptide‐MsrA Fusion Protein Restores HDL Function and Ameliorates Atherosclerosis via Circulatory Redox Remodeling in SR‐BI Deficient Mice
The redox imbalance in circulation can lead to inflammation and cellular damage in vascular walls, which plays a crucial role in atherogenesis. We previously designed an apolipoprotein E (ApoE) mimetic peptide, EpK, which can reduce atherosclerosis in ApoE‐deficient mice by binding high‐density lipoprotein (HDL). Meanwhile, hepatic overexpression of methionine sulfoxide reductase A (MsrA) can exert indirect anti‐atherosclerotic effects. Therefore, exploring biomolecules that directly promote circulatory redox rebalance is significant for the therapy of atherosclerotic cardiovascular diseases (ASCVD). MsrA was recombined with EpK to achieve the secretory expression of EpK‐MsrA. Our experiments revealed that EpK and EpK‐MsrA significantly improved the oxidative state and inflammatory composition of dysfunctional HDL and promoted hepatic cholesterol uptake and excretion, thereby alleviating atherosclerosis and hepatic steatosis in scavenger receptor class B type I deficient (SR‐BI −/− ) mice. Furthermore, compared with EpK, EpK‐MsrA had a stronger anti‐inflammatory and regulatory effect on HDL functional proteins, such as apolipoprotein AI (ApoAI), paraoxonase 1 (PON1), and lecithin cholesterol acyltransferase (LCAT), thereby further reducing atherosclerosis. Additionally, exogenous EpK‐MsrA may be able to regenerate its antioxidant activity through EpK recycling. This study suggests that novel secreted EpK‐MsrA can combine the different antioxidant mechanisms of EpK and MsrA, significantly improve the functional proteins related to lipid metabolism and inflammation, and effectively alleviate atherosclerosis in SR‐BI −/− mice, which may be a promising strategy for the treatment of ASCVD.
- Open Access
- 14 February 2025
- Published by Wiley in Advanced Science
- Vol. 12 (14) , e2413299
Adrenal High‐Expressional CYP27A1 Mediates Bile Acid Increase and Functional Impairment in Adult Male Offspring by Prenatal Dexamethasone Exposure
Prenatal dexamethasone exposure (PDE) can impact adrenal corticosteroid synthesis in adult offspring. Furthermore, the adrenal gland can autonomously synthesize bile acids, but local bile acids accumulation has cytotoxic effects. This study found that PDE increased histone 3 lysine 27 acetylation (H3K27ac) levels in the promoter region of cholesterol 27 hydroxylase (CYP27A1) and its expression, as well as total bile acids (TBA) concentrations and enhanced endoplasmic reticulum stress (ERS) and inhibit steroid synthesis in adult male offspring rat adrenal glands. However, it is reversed in females. Tracing back to the prenatal stage and in combination with cellular experiments, it is further revealed that dexamethasone can regulate glucocorticoid receptor (GR)/SET binding protein 1 (SETBP1)/CYP27A1 signal pathway, consequently cause intracellular increase of bile acids. Finally, administration of nilvadipine (CYP27A1 inhibitor) to male offspring for 4 weeks after birth resulted in the reversal of PDE‐induced adrenal morphological and functional damage. In conclusion, PDE induces fetal adrenal corticosteroid dysfunction in adult male offspring by upregulating CYP27A1 promoter region H3K27ac levels and expression in the adrenal gland through the GR/SETBP1 signaling pathway. This effect persists beyond birth, leading to bile acids local increase and subsequent enhancement of ERS, ultimately inducing cellular dysfunction in adult adrenal glands.
- 14 February 2025
- Published by Wiley in Advanced Science
- Vol. 12 (14) , e2413299
Open AccessAdrenal High‐Expressional CYP27A1 Mediates Bile Acid Increase and Functional Impairment in Adult Male Offspring by Prenatal Dexamethasone Exposure
Prenatal dexamethasone exposure (PDE) can impact adrenal corticosteroid synthesis in adult offspring. Furthermore, the adrenal gland can autonomously synthesize bile acids, but local bile acids accumulation has cytotoxic effects. This study found that PDE increased histone 3 lysine 27 acetylation (H3K27ac) levels in the promoter region of cholesterol 27 hydroxylase (CYP27A1) and its expression, as well as total bile acids (TBA) concentrations and enhanced endoplasmic reticulum stress (ERS) and inhibit steroid synthesis in adult male offspring rat adrenal glands. However, it is reversed in females. Tracing back to the prenatal stage and in combination with cellular experiments, it is further revealed that dexamethasone can regulate glucocorticoid receptor (GR)/SET binding protein 1 (SETBP1)/CYP27A1 signal pathway, consequently cause intracellular increase of bile acids. Finally, administration of nilvadipine (CYP27A1 inhibitor) to male offspring for 4 weeks after birth resulted in the reversal of PDE‐induced adrenal morphological and functional damage. In conclusion, PDE induces fetal adrenal corticosteroid dysfunction in adult male offspring by upregulating CYP27A1 promoter region H3K27ac levels and expression in the adrenal gland through the GR/SETBP1 signaling pathway. This effect persists beyond birth, leading to bile acids local increase and subsequent enhancement of ERS, ultimately inducing cellular dysfunction in adult adrenal glands.
- 1 July 2024
- Published by SAGE Publications in Antioxidants & Redox Signaling
- Vol. 41 (1-3) , 56-73
Scavenger Receptor Class B Type I Deficiency Induces Iron Overload and Ferroptosis in Renal Tubular Epithelial Cells via Hypoxia-Inducible Factor-1α/Transferrin Receptor 1 Signaling Pathway
Aims: Scavenger receptor class B type I (SRBI) promotes cell cholesterol efflux and the clearance of plasma cholesterol. Thus, SRBI deficiency causes abnormal cholesterol metabolism and hyperlipidemia. Studies have suggested that ferroptosis is involved in lipotoxicity; however, whether SRBI deficiency could induce ferroptosis remains to be investigated. Results: We knocked down or knocked out SRBI in renal HK-2 cells and C57BL/6 mice to determine the expression levels of ferroptosis-related regulators. Our results demonstrated that SRBI deficiency upregulates transferrin receptor 1 (TFR1) expression and downregulates ferroportin (FPN) expression, which induces iron overload and subsequent ferroptosis in renal tubular epithelial cells. TFR1 is known to be regulated by hypoxia-inducible factor-1α (HIF-1α). Next, we investigated whether SRBI deletion affected HIF-1α. SRBI deletion upregulated the mRNA and protein expression of HIF-1α and promoted its translocation to the nucleus. To determine whether HIF-1α plays a key role in SRBI-deficiency-induced ferroptosis, we used HIF-1α inhibitor and siHIF-1α in HK-2 cells and found that downregulation of HIF-1α prevented SRBI-silencing-induced TFR1 upregulation and iron overload, and eventually reduced ferroptosis. The underlying mechanism of HIF-1α activation was explored next, and the results showed that SRBI knockout or knockdown may upregulate the expression of HIF-1α and promote HIF-1α translocation from the cytoplasm into the nucleus via the PKC-β/NF-κB signaling pathway. Innovation and Conclusion: Our study showed, for the first time, that SRBI deficiency induces iron overload and subsequent ferroptosis via the HIF-1α/TFR1 pathway.
- 1 July 2024
- Published by SAGE Publications in Antioxidants & Redox Signaling
- Vol. 41 (1-3) , 56-73
Scavenger Receptor Class B Type I Deficiency Induces Iron Overload and Ferroptosis in Renal Tubular Epithelial Cells via Hypoxia-Inducible Factor-1α/Transferrin Receptor 1 Signaling Pathway
Aims: Scavenger receptor class B type I (SRBI) promotes cell cholesterol efflux and the clearance of plasma cholesterol. Thus, SRBI deficiency causes abnormal cholesterol metabolism and hyperlipidemia. Studies have suggested that ferroptosis is involved in lipotoxicity; however, whether SRBI deficiency could induce ferroptosis remains to be investigated. Results: We knocked down or knocked out SRBI in renal HK-2 cells and C57BL/6 mice to determine the expression levels of ferroptosis-related regulators. Our results demonstrated that SRBI deficiency upregulates transferrin receptor 1 (TFR1) expression and downregulates ferroportin (FPN) expression, which induces iron overload and subsequent ferroptosis in renal tubular epithelial cells. TFR1 is known to be regulated by hypoxia-inducible factor-1α (HIF-1α). Next, we investigated whether SRBI deletion affected HIF-1α. SRBI deletion upregulated the mRNA and protein expression of HIF-1α and promoted its translocation to the nucleus. To determine whether HIF-1α plays a key role in SRBI-deficiency-induced ferroptosis, we used HIF-1α inhibitor and siHIF-1α in HK-2 cells and found that downregulation of HIF-1α prevented SRBI-silencing-induced TFR1 upregulation and iron overload, and eventually reduced ferroptosis. The underlying mechanism of HIF-1α activation was explored next, and the results showed that SRBI knockout or knockdown may upregulate the expression of HIF-1α and promote HIF-1α translocation from the cytoplasm into the nucleus via the PKC-β/NF-κB signaling pathway. Innovation and Conclusion: Our study showed, for the first time, that SRBI deficiency induces iron overload and subsequent ferroptosis via the HIF-1α/TFR1 pathway.
- Open Access
- 28 May 2024
- Published by Impact Journals, LLC in Aging
- Vol. 16 (10) , 9264-9279
Bufotalin enhances apoptosis and TMZ chemosensitivity of glioblastoma cells by promoting mitochondrial dysfunction via AKT signaling pathway
Glioblastoma multiforme (GBM) is the most prevalent and lethal primary intracranial neoplasm in the adult population, with treatments of limited efficacy. Recently, bufotalin has been shown to have anti-cancer activity in a variety of cancers. This investigation aims to investigate the effect of bufotalin on GBM and elucidate its potential underlying mechanism. Our results show that bufotalin not only inhibits the proliferation and epithelial-mesenchymal transition (EMT) but also triggers apoptosis in GBM cells. The result of RNA-seq indicated that bufotalin could induce mitochondrial dysfunction. Moreover, our observations indicate that bufotalin induces an excessive accumulation of intracellular reactive oxygen species (ROS) in GBM cells, leading to mitochondrial dysfunction and the dephosphorylation of AKT. Moreover, bufotalin improved TMZ sensitivity of GBM cells in vitro and in vivo. In conclusion, bufotalin enhances apoptosis and TMZ chemosensitivity of glioblastoma cells by promoting mitochondrial dysfunction via AKT signaling pathway.
- 28 May 2024
- Published by Impact Journals, LLC in Aging
- Vol. 16 (10) , 9264-9279
Open AccessBufotalin enhances apoptosis and TMZ chemosensitivity of glioblastoma cells by promoting mitochondrial dysfunction via AKT signaling pathway
Glioblastoma multiforme (GBM) is the most prevalent and lethal primary intracranial neoplasm in the adult population, with treatments of limited efficacy. Recently, bufotalin has been shown to have anti-cancer activity in a variety of cancers. This investigation aims to investigate the effect of bufotalin on GBM and elucidate its potential underlying mechanism. Our results show that bufotalin not only inhibits the proliferation and epithelial-mesenchymal transition (EMT) but also triggers apoptosis in GBM cells. The result of RNA-seq indicated that bufotalin could induce mitochondrial dysfunction. Moreover, our observations indicate that bufotalin induces an excessive accumulation of intracellular reactive oxygen species (ROS) in GBM cells, leading to mitochondrial dysfunction and the dephosphorylation of AKT. Moreover, bufotalin improved TMZ sensitivity of GBM cells in vitro and in vivo. In conclusion, bufotalin enhances apoptosis and TMZ chemosensitivity of glioblastoma cells by promoting mitochondrial dysfunction via AKT signaling pathway.
- 10 August 2022
- Published by Elsevier in The American Journal of Pathology
- Vol. 192 (11) , 1531-1545
Paraoxonase 1 Ameliorates Renal Lipotoxicity by Activating Lipophagy and Inhibiting Pyroptosis
- 10 August 2022
- Published by Elsevier in The American Journal of Pathology
- Vol. 192 (11) , 1531-1545
Paraoxonase 1 Ameliorates Renal Lipotoxicity by Activating Lipophagy and Inhibiting Pyroptosis
- 17 May 2022
- Published by Springer Nature
- Vol. 1377, 79-93
HDL and Scavenger Receptor Class B Type I (SRBI)
The scavenger receptor class B type I (SR-BI) is a versatile HDL receptor protein. It is highly expressed in liver and steroidogenic tissues. SR-BI regulates selective uptake of cholesterol ester (CE) from HDL, revealing its role in mediating reverse cholesterol transport (RCT) and steroid hormone synthesis. In addition, SR-BI is involved in cholesterol transport, cellular inflammatory response, platelet reactivity, and HDL-initiated signaling in the vascular system in several mouse models. Mutations in the human SR-BI gene (SCARB1) have been found to be associated with abnormally high plasma HDL-C levels and an increased risk of atherosclerotic cardiovascular disease. At present, the key regions of SR-BI transmembrane structure and the regulatory mechanisms of SR-BI expression still need to be further studied. In this chapter, the structural, functional, and regulatory characteristics of SR-BI are reviewed, and the importance of SR-BI in related metabolic diseases was expounded. Keywords Scavenger receptor class B type I (SR-BI) HDL metabolism Reverse cholesterol transport Cholesterol transport Cellular inflammatory response Platelet reactivity HDL-initiated signaling Atherosclerotic cardiovascular disease
- 17 May 2022
- Published by Springer Nature
- Vol. 1377, 79-93
HDL and Scavenger Receptor Class B Type I (SRBI)
The scavenger receptor class B type I (SR-BI) is a versatile HDL receptor protein. It is highly expressed in liver and steroidogenic tissues. SR-BI regulates selective uptake of cholesterol ester (CE) from HDL, revealing its role in mediating reverse cholesterol transport (RCT) and steroid hormone synthesis. In addition, SR-BI is involved in cholesterol transport, cellular inflammatory response, platelet reactivity, and HDL-initiated signaling in the vascular system in several mouse models. Mutations in the human SR-BI gene (SCARB1) have been found to be associated with abnormally high plasma HDL-C levels and an increased risk of atherosclerotic cardiovascular disease. At present, the key regions of SR-BI transmembrane structure and the regulatory mechanisms of SR-BI expression still need to be further studied. In this chapter, the structural, functional, and regulatory characteristics of SR-BI are reviewed, and the importance of SR-BI in related metabolic diseases was expounded. Keywords Scavenger receptor class B type I (SR-BI) HDL metabolism Reverse cholesterol transport Cholesterol transport Cellular inflammatory response Platelet reactivity HDL-initiated signaling Atherosclerotic cardiovascular disease